1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsThis grant from the NIH aims to advance the science and implementation of innovative multi-level healthcare research for older adults from populations experiencing health disparities.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →According to the current listing, eligibility includes: This program is primarily for organizations, but individuals may be eligible as part of a research team or through specific career development awards. Confirm the full requirements in the official notice before applying.
Applications for Advancing Healthcare for Older Adults from Populations that Experience Health Disparities (PAR-24-273) are due January 7, 2028. Build your timeline backwards from this date to cover registrations, approvals, and final submission checks.
Advancing Healthcare for Older Adults from Populations that Experience Health Disparities (PAR-24-273) is funded by National Institutes of Health (NIH). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Past winners and funding trends for this program
PCORI Cycle 2 2026 Methods Funding Announcement specifically prioritizes Methods to Improve the Use of Artificial Intelligence (AI) and Machine Learning (ML) in Patient-Centered Comparative Effectiveness Research (CER). The program funds studies addressing high-impact methodological gaps, with AI/ML topics including applications of AI/ML to augment or transform research methodologies or processes and approaches using AI/ML to enhance health communication. Additional priority areas include Methods to Support Use of Real-World Data in Multi-Site Patient-Centered CER and Methods to Improve Study Design. Awards provide up to $750,000 in direct costs for up to 3 years from a total program budget of $12 million. Applicants must address PCORI Foundational Expectations for Partnerships in Research, ensuring patients and stakeholders meaningfully contribute lived experience. Letter of Intent deadline is April 28, 2026, with full applications due September 1, 2026.
Equity in Access Research Grants is sponsored by Blood Cancer United. This Request for Proposals (RFP) funds research that advances understanding of how insurance status, type, design, and policy changes create barriers to equitable access to cancer care, and identifies actionable solutions to address these barriers through policy reform and changes in healthcare practice and program delivery. The program aims to generate new evidence that can guide policy reform and changes in healthcare practice, in order to mitigate the impact of social, economic and environmental disadvantages and reduce barriers to care.
PA-27-037 consolidates the Predoctoral to Postdoctoral Transition Award into a single parent announcement across 20 NIH components, with the next deadline December 8, 2026. The eligibility gate is not the science — it is a mandatory change of institution and mentor between the F99 and K00 phases.
Read articleA draft executive order would have put OMB Director Russell Vought on a commission with final say over NIH awards after peer review. Sen. Collins killed it by pointing at a provision Congress already passed. Here is what the episode teaches applicants about the December 11 cliff.
Read articlePA-27-034, PA-27-035 and PA-27-036 replace the institute-specific R25 announcements that research education programs have been built around for a decade. NCI, NIDA and NIGMS have already expired theirs early. Here is what the consolidation actually changes: an 8% indirect cost ceiling, a US-citizens-and-permanent-residents participant rule, a cooperative agreement variant that only exists on one of the three, and no clinical-trial-allowed companion anywhere.
Read article